GLP-1 Weight Loss Medication and Medical Aid Coverage in South Africa (2026)
GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro have changed the weight loss conversation in South Africa. But one question keeps coming up: will my medical aid actually pay for it?
The short answer is: it depends on your plan, the medication, and why your doctor is prescribing it. This guide breaks down the current state of GLP-1 medical aid coverage in South Africa so you can plan ahead financially.
How Medical Aid Coverage Works for Weight Loss Medication
South African medical aids operate under the Medical Schemes Act, which mandates Prescribed Minimum Benefits (PMBs) -- a set of conditions and treatments every registered scheme must cover. Type 2 diabetes is a PMB condition, and insulin-sensitising or glucose-lowering drugs prescribed for it are generally covered.
However, obesity on its own is not currently a PMB condition in South Africa. This is the crux of the coverage challenge. If your doctor prescribes semaglutide (Ozempic) for type 2 diabetes, your medical aid is obligated to cover it. If the same medication is prescribed purely for weight management in a patient without diabetes, the scheme can decline coverage.
The diabetes vs weight loss distinction
- Prescribed for diabetes (PMB): Medical aid must cover the cost on most plans
- Prescribed for weight loss only: Coverage depends on your specific plan and scheme rules
- Prescribed for weight loss with comorbidities: Stronger case for ex-gratia approval (see below)
GLP-1 Coverage by Major South African Medical Aids
Coverage policies differ across schemes and are updated annually. The table below reflects general positions as of mid-2026 -- always verify with your specific scheme.
| Medical Aid | Ozempic (Diabetes) | Ozempic (Weight Loss) | Wegovy | Mounjaro |
|---|---|---|---|---|
| Discovery Health | Covered (PMB) | Limited / ex-gratia | Not routinely covered | Not covered (unregistered) |
| Momentum Health | Covered (PMB) | Plan-dependent | Not routinely covered | Not covered (unregistered) |
| Bonitas | Covered (PMB) | Limited / ex-gratia | Not routinely covered | Not covered (unregistered) |
| Medshield | Covered (PMB) | Plan-dependent | Not routinely covered | Not covered (unregistered) |
| GEMS | Covered (PMB) | Generally not covered | Not routinely covered | Not covered (unregistered) |
What Is an Ex-Gratia Application?
If your plan does not routinely cover GLP-1 medication for weight loss, you (or your doctor) can submit an ex-gratia application. This is a formal request asking the medical aid to make an exception and cover treatment outside the standard benefit schedule.
How to strengthen your ex-gratia application
- Doctor's motivation letter -- detailing your BMI, health history, and why GLP-1 therapy is medically necessary
- Documented comorbidities -- hypertension, pre-diabetes, sleep apnoea, polycystic ovary syndrome (PCOS), or cardiovascular risk factors
- Evidence of failed lifestyle interventions -- documented attempts at diet, exercise, and behavioural changes over at least 6-12 months
- Blood work and clinical assessments -- HbA1c, fasting insulin, lipid panels, liver function tests
- BMI threshold -- most schemes take applications more seriously for patients with BMI above 35, or above 30 with comorbidities
Approval is never guaranteed. Some schemes approve partial coverage (such as paying from your medical savings account or day-to-day benefits), while others may agree to cover a defined treatment period of 6-12 months.
Out-of-Pocket Costs: What to Expect in 2026
If your medical aid does not cover your GLP-1 medication, here is what you are likely to pay at a South African pharmacy:
| Medication | Indication | Estimated Monthly Cost (ZAR) | SAHPRA Status |
|---|---|---|---|
| Ozempic (semaglutide 0.5-1 mg) | Type 2 diabetes | R1,800 - R3,500 | Registered |
| Wegovy (semaglutide 2.4 mg) | Weight management | R2,500 - R4,500 | Registered |
| Mounjaro (tirzepatide) | Diabetes / weight loss | R3,000 - R6,000 | Not yet registered (Section 21) |
| Rybelsus (oral semaglutide) | Type 2 diabetes | R1,500 - R2,800 | Registered |
Prices are based on Single Exit Price (SEP) schedules and pharmacy reports. Actual costs vary between pharmacies and may change with annual SEP adjustments. Always confirm current pricing before committing to treatment.
For a detailed cost breakdown, see our Ozempic cost guide and Mounjaro pricing article.
Strategies to Reduce Your Out-of-Pocket Costs
- Use your medical savings account (MSA): Even if chronic benefits do not cover GLP-1s for weight loss, your MSA or day-to-day benefits may apply. Check your available balance.
- Ask about generic semaglutide: As patents evolve, generic options may become available at lower prices. Ask your pharmacist about alternatives.
- Compare pharmacy prices: SEP sets the maximum, but some pharmacies charge less. Use dispensing fee comparisons to save a few hundred rand per month.
- Combine with lifestyle changes: A solid eating plan and regular walking can help you reach goals faster, potentially shortening the duration of medication use.
- Consider oral options: Rybelsus (oral semaglutide) at lower doses may cost less than injectable forms while still providing benefits.
Will Medical Aid Coverage Improve?
There are signs that the landscape is shifting. Globally, more insurance providers are recognising obesity as a chronic disease requiring pharmaceutical intervention. In South Africa:
- The Council for Medical Schemes periodically reviews the PMB list. Advocacy groups are pushing for obesity-related treatments to be included.
- Some schemes are piloting integrated weight management programmes that include medication as one component alongside dietitian support and exercise coaching.
- As Wegovy pricing becomes more competitive and more GLP-1 options enter the market, cost-effectiveness arguments strengthen.
- Real-world evidence showing reduced cardiovascular events and healthcare costs in patients using GLP-1s may accelerate policy changes.
For now, the practical reality is that most South Africans paying for GLP-1 weight loss medication are doing so at least partly out of pocket. Planning your budget accordingly is essential.
What to Ask Your Doctor and Your Medical Aid
Before starting GLP-1 treatment, have these conversations:
Questions for your doctor
- Based on my health profile, which GLP-1 medication is most appropriate?
- Can you code this prescription in a way that maximises my medical aid benefit?
- Are you willing to submit an ex-gratia motivation on my behalf?
- What is the realistic treatment timeline, and what happens when I stop?
Questions for your medical aid
- Does my plan cover semaglutide or tirzepatide for weight management specifically?
- What is the ex-gratia application process and typical turnaround time?
- Can I use my medical savings account or day-to-day benefits for this medication?
- Does my plan include any obesity management or chronic weight programmes?
Planning Your GLP-1 Journey?
Start with the basics: our complete GLP-1 guide covers how these medications work, who qualifies, and what results to expect. For cost comparisons, see our semaglutide comparison page.
The Bottom Line
GLP-1 medications are effective tools for weight management, but accessing them affordably through South African medical aids remains a challenge in 2026. If you have type 2 diabetes, coverage for Ozempic is generally straightforward. If your goal is weight loss without a diabetes diagnosis, expect to navigate ex-gratia applications and potentially fund a significant portion out of pocket.
The good news is that the landscape is evolving. More medical aids are exploring weight management programmes, and as competition between GLP-1 manufacturers increases, pricing pressure should work in patients' favour over time.
Whatever route you take, combine medication with sustainable lifestyle changes -- a balanced eating plan rich in local whole foods like lean biltong, vegetables, legumes, and rooibos tea, alongside regular physical activity. Medication works best as part of a bigger picture, not a standalone solution.